Citigroup Raises Zoetis (NYSE:ZTS) Price Target to $146.00
Zoetis (NYSE:ZTS) had its price target raised by Citigroup from $131.00 to $146.00 in a research note released on Thursday morning, BenzingaRatingsTable reports. They currently have a neutral rating on the stock.
Other analysts also recently issued research reports about the company. Argus reaffirmed a buy rating on shares of Zoetis in a research note on Wednesday, June 3rd. Barclays lifted their price objective on shares of Zoetis from $129.00 to $140.00 and gave the company an overweight rating in a research note on Thursday, May 7th. UBS Group reduced their price objective on shares of Zoetis from $146.00 to $126.00 and set a neutral rating for the company in a report on Friday, May 8th. Morgan Stanley lowered their target price on shares of Zoetis from $148.00 to $125.00 and set an equal weight rating on the stock in a research note on Thursday, April 2nd. Finally, Credit Suisse Group restated a buy rating and set a $147.00 price target on shares of Zoetis in a research report on Monday, May 18th. Seven research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $143.79.
ZTS stock opened at $151.68 on Thursday. The stock has a market cap of $72.04 billion, a PE ratio of 45.28, a price-to-earnings-growth ratio of 4.85 and a beta of 0.77. The firm’s 50-day simple moving average is $138.92 and its 200 day simple moving average is $132.73. Zoetis has a fifty-two week low of $90.14 and a fifty-two week high of $151.91. The company has a quick ratio of 1.91, a current ratio of 2.77 and a debt-to-equity ratio of 2.22.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 17th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.53%. The ex-dividend date is Thursday, July 16th. Zoetis’s dividend payout ratio is presently 21.98%.
In other news, EVP Roxanne Lagano sold 4,463 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $131.02, for a total transaction of $584,742.26. Following the sale, the executive vice president now directly owns 40,143 shares of the company’s stock, valued at $5,259,535.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Heidi C. Chen sold 1,179 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $138.65, for a total value of $163,468.35. Following the sale, the executive vice president now directly owns 17,514 shares of the company’s stock, valued at $2,428,316.10. The disclosure for this sale can be found here. Insiders have sold 17,321 shares of company stock valued at $2,288,831 over the last 90 days. 0.17% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in the business. Lion Street Advisors LLC acquired a new stake in shares of Zoetis during the first quarter valued at approximately $30,000. Truvestments Capital LLC purchased a new position in Zoetis during the 1st quarter worth approximately $33,000. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in Zoetis by 99.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 289 shares of the company’s stock valued at $34,000 after purchasing an additional 144 shares during the period. Campbell Wealth Management purchased a new stake in shares of Zoetis in the second quarter valued at $34,000. Finally, New England Investment & Retirement Group Inc. acquired a new stake in shares of Zoetis in the first quarter worth $35,000. Institutional investors own 91.42% of the company’s stock.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Technical Analysis
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.